You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
News items for the week of Jan. 4, 2021.
The Roche subsidiary will take over development of RLY-1971 and study it in combination with other drugs, such as its KRAS G12C inhibitor GDC-6036.
Researchers presented data exploring CLL patients' outcomes on fixed-duration combination regimens and on using uMRD to decide which patients can stop treatment.
This is the second precision oncology drug approved by the agency for patients with RET-mutant medullary thyroid cancer or RET fusion-positive thyroid cancer.
The partnership goes hand-in-hand with Genentech's new precision basket trial, for which it will identify and enroll patients across OneOncology's network.
The researchers said their findings could explain improved outcomes of sarcomatoid tumors to checkpoint blockade versus antiangiogenic therapies alone.
Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.
FoundationOne Liquid CDx can now be used as a companion diagnostic for therapies to treat advanced ovarian, breast, and non-small cell lung cancer.
The Norwegian company will receive $200 million upfront from Genentech for the rights to its investigational neoantigen-based cancer vaccine, VB10.NEO.